Critical Comparison: Brainsway (NASDAQ:BWAY) versus FluoroPharma Medical (OTCMKTS:FPMI)

Brainsway (NASDAQ:BWAY) and FluoroPharma Medical (OTCMKTS:FPMI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Brainsway and FluoroPharma Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainsway	11.60%	8.97%	5.65%
FluoroPharma Medical	N/A	N/A	N/A

Insider & Institutional Ownership

30.1% of Brainsway shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 36.9% of FluoroPharma Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Brainsway and FluoroPharma Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0	0	2	0	3.00
FluoroPharma Medical	0	0	0	0	0.00

Brainsway presently has a consensus target price of $18.00, indicating a potential upside of 16.35%. Given Brainsway’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainsway is more favorable than FluoroPharma Medical.

Earnings & Valuation

This table compares Brainsway and FluoroPharma Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$41.02 million	7.13	$2.92 million	$0.26	59.50
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A

Brainsway has higher revenue and earnings than FluoroPharma Medical.

Summary

Brainsway beats FluoroPharma Medical on 8 of the 9 factors compared between the two stocks.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.